Pembrolizumab (PBL)

[Edit]

Keytruda; 1374853-91-4; DPT0O3T46P; MK-3475

Pembrolizumab (PBL)

Pembrolizumab is a novel cancer treatment drug that targets PD-1 receptors on cancer cells to stimulate the immune system to attack the tumor. It is a highly selective IgG4-kappa humanized monoclonal antibody. Approved by the FDA, it has shown promising results in treating various cancers, such as melanoma and HER2-positive breast and gastric cancers. It is typically administered intravenously at a dose of 2mg/kg every three weeks. However, like any medication, it may cause side effects such as digestive discomfort, fatigue, and skin reactions. Therefore, it's crucial to follow the doctor's instructions for safe and effective use.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Pembrolizumab (PBL) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Pembrolizumab (PBL) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Pembrolizumab (PBL) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Pembrolizumab (PBL) CLIA Kit Customized Service Offer
n/a ELISA Kit for Pembrolizumab (PBL) ELISA Kit Customized Service Offer